Niagen Bioscience, Inc. — Director's Dealing 2024

Nov 25, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2024-11-22

Reporting Person: Pamir Ozan (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-22	Common Stock	P	2907.197	$7.36	Acquired	2907.197	Direct

Footnotes

F1: The weighted average purchase price for the transaction reported was $7.36, and the range of prices were between $7.345 and $7.36, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided.